eXoZymes (EXOZ) Competitors $9.31 0.00 (0.00%) As of 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock EXOZ vs. RCKT, ALT, BNTC, ALDX, CADL, ACB, FDMT, AMRN, DMAC, and DSGNShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Rocket Pharmaceuticals (RCKT), Altimmune (ALT), Benitec Biopharma (BNTC), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), Aurora Cannabis (ACB), 4D Molecular Therapeutics (FDMT), Amarin (AMRN), DiaMedica Therapeutics (DMAC), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Rocket Pharmaceuticals Altimmune Benitec Biopharma Aldeyra Therapeutics Candel Therapeutics Aurora Cannabis 4D Molecular Therapeutics Amarin DiaMedica Therapeutics Design Therapeutics Rocket Pharmaceuticals (NASDAQ:RCKT) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Does the media favor RCKT or EXOZ? In the previous week, Rocket Pharmaceuticals had 30 more articles in the media than eXoZymes. MarketBeat recorded 30 mentions for Rocket Pharmaceuticals and 0 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.67 beat Rocket Pharmaceuticals' score of 0.14 indicating that eXoZymes is being referred to more favorably in the news media. Company Overall Sentiment Rocket Pharmaceuticals Neutral eXoZymes Positive Do analysts prefer RCKT or EXOZ? Rocket Pharmaceuticals currently has a consensus price target of $16.73, suggesting a potential upside of 359.71%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Rocket Pharmaceuticals is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, RCKT or EXOZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.45eXoZymesN/AN/A-$5.86MN/AN/A Is RCKT or EXOZ more profitable? Rocket Pharmaceuticals' return on equity of -65.11% beat eXoZymes' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -65.11% -55.99% eXoZymes N/A -134.50%-81.63% Do insiders and institutionals have more ownership in RCKT or EXOZ? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryRocket Pharmaceuticals beats eXoZymes on 7 of the 10 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.08M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E RatioN/A21.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book10.838.079.116.39Net Income-$5.86M-$54.72M$3.26B$265.66M7 Day Performance-4.02%2.62%2.11%1.98%1 Month Performance1.31%7.63%5.12%1.33%1 Year PerformanceN/A13.11%31.25%21.15% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$9.31flatN/AN/A$78.08MN/A0.0029News CoveragePositive NewsGap UpRCKTRocket Pharmaceuticals4.8877 of 5 stars$3.03-1.9%$16.33+439.1%-81.4%$333.42MN/A-1.21240Analyst ForecastAnalyst RevisionALTAltimmune3.2899 of 5 stars$3.68-1.6%$17.40+372.8%-48.6%$330.08M$20K-3.1250Trending NewsBNTCBenitec Biopharma1.4454 of 5 stars$12.66+1.2%$26.00+105.4%+41.7%$328.39M$80K-8.3820News CoverageALDXAldeyra Therapeutics2.1231 of 5 stars$5.30-1.3%$9.50+79.2%+9.7%$321.64MN/A-6.2410CADLCandel Therapeutics2.6155 of 5 stars$6.04-5.6%$22.00+264.2%+10.1%$320.66M$120K-4.5160ACBAurora Cannabis1.0056 of 5 stars$5.39-2.5%N/A-25.2%$312.19M$246.72M-28.371,130FDMT4D Molecular Therapeutics2.1396 of 5 stars$7.10+6.4%$30.40+328.2%-54.9%$311.51M$40K-2.01120AMRNAmarin0.2717 of 5 stars$15.04+0.3%$12.00-20.2%+22.1%$310.61M$228.61M-4.10360Positive NewsDMACDiaMedica Therapeutics1.5951 of 5 stars$6.01+0.2%$10.75+78.9%+60.3%$310.13MN/A-8.7120Short Interest ↑DSGNDesign Therapeutics0.1666 of 5 stars$5.16-4.8%N/A-1.9%$308.66MN/A-4.6140 Related Companies and Tools Related Companies Rocket Pharmaceuticals Competitors Altimmune Competitors Benitec Biopharma Competitors Aldeyra Therapeutics Competitors Candel Therapeutics Competitors Aurora Cannabis Competitors 4D Molecular Therapeutics Competitors Amarin Competitors DiaMedica Therapeutics Competitors Design Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access